Huntington disease: natural history, biomarkers and prospects for therapeutics (Q30774172)

26 June 2017

1 reference

title

Huntington disease: natural history, biomarkers and prospects for therapeutics (English)

1 reference

26 June 2017

0 references

0 references

1 reference

26 June 2017

1 reference

26 June 2017

Ralf Reilmann

0 references

Douglas R Langbehn

0 references

Jeffrey D Long

0 references

Jane S Paulsen

0 references

Julie C Stout

0 references

Paul G Unschuld

0 references

Christopher A Ross

1 reference

26 June 2017

Blair R Leavitt

1 reference

26 June 2017

Rachael I Scahill

1 reference

26 June 2017

Russell L Margolis

1 reference

26 June 2017

Elizabeth H Aylward

1 reference

26 June 2017

John H Warner

series ordinal

1 reference

26 June 2017

Alice Wexler

series ordinal

1 reference

26 June 2017

language of work or name

English

0 references

publication date

11 March 2014

1 reference

26 June 2017

published in

Nature Reviews Neurology

1 reference

26 June 2017

1 reference

26 June 2017

1 reference

26 June 2017

page(s)

204-216

1 reference

Huntington's disease: how intermediate are intermediate repeat lengths?

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Unified Huntington's disease rating scale: Reliability and consistency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Interrater agreement in the assessment of motor manifestations of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Development of biomarkers for Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Huntington disease: Clinical care and evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Detection of Huntington's disease decades before diagnosis: the Predict-HD study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Predictors of neuropathological severity in 100 patients with Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Age, CAG repeat length, and clinical progression in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

CAG repeat number governs the development rate of pathology in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Indexing disease progression at study entry with individuals at-risk for Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Randomized controlled clinical trial of "virtual house calls" for Parkinson disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

The association of CAG repeat length with clinical progression in Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Tapping linked to function and structure in premanifest and symptomatic Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Objective assessment of progression in Huntington's disease: a 3-year follow-up study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Grasping premanifest Huntington's disease - shaping new endpoints for new trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Neurocognitive signs in prodromal Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Psychomotor, executive, and memory function in preclinical Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Cognitive and functional decline in Huntington's disease: dementia criteria revisited

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Verbal episodic memory declines prior to diagnosis in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

"Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Therapeutics in Huntington's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Harnessing immune alterations in neurodegenerative diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Immune markers for Huntington's disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Early defect of transforming growth factor β1 formation in Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Beta conformation of polyglutamine track revealed by a crystal structure of Huntingtin N-terminal region with insertion of three histidine residues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Impairment of the ubiquitin-proteasome system by protein aggregation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

What have we learned from gene expression profiles in Huntington's disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Familial influence on age of onset among siblings with Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Huntington's disease: seeing the pathogenic process through a genetic lens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Analysis of genetic inheritance in a family quartet by whole-genome sequencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Huntington's disease: from molecular pathogenesis to clinical treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Longitudinal change in basal ganglia volume in patients with Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Striatal volume loss in HD as measured by MRI and the influence of CAG repeat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Magnetization transfer MR imaging demonstrates degeneration of the subcortical and cortical gray matter in Huntington disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Seeking Huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Longitudinal change in regional brain volumes in prodromal Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Striatal and white matter predictors of estimated diagnosis for Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Cerebral cortex structure in prodromal Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

The distribution of structural neuropathology in pre-clinical Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Brain structure in preclinical Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

White matter volume and cognitive dysfunction in early Huntington's disease

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

31 March 2020

12 December 2020

Shape analysis of subcortical nuclei in Huntington's disease, global versus local atrophy--results from the TRACK-HD study

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

In vivo evidence for the selective subcortical degeneration in Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Regional distribution and clinical correlates of white matter structural damage in Huntington disease: a tract-based spatial statistics study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection".

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Diffusion tensor imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

The structural correlates of functional deficits in early huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Functional brain changes in presymptomatic Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Functional imaging in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Altered brain mechanisms of emotion processing in pre-manifest Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Magnetization transfer imaging in premanifest and manifest Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Functional compensation of motor function in pre-symptomatic Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Default-mode network changes in preclinical Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Paralimbic frontal lobe hypometabolism in depression associated with Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Irritability in pre-clinical Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Depressive symptoms in prodromal Huntington's Disease correlate with Stroop-interference related functional connectivity in the ventromedial prefrontal cortex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Prefrontal executive function associated coupling relates to Huntington's disease stage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Altered frontostriatal coupling in pre-manifest Huntington's disease: effects of increasing cognitive load.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Proton MRS in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Brain metabolite alterations and cognitive dysfunction in early Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Alterations in brain transition metals in Huntington disease: an evolving and intricate story

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Evaluating imaging biomarkers for neurodegeneration in pre-symptomatic Huntington's disease using machine learning techniques

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Variation of selective gray and white matter atrophy in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Atypical movement disorders in the early stages of Huntington's disease: clinical and genetic analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Highly disabling cerebellar presentation in Huntington disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible Biomarker of Disease Progression?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Thalamic metabolism and symptom onset in preclinical Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Brain networks in Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Metabolic network as a progression biomarker of premanifest Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Striatal volume contributes to the prediction of onset of Huntington disease in incident cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Biomarkers for Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Biomarkers for Huntington's disease: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

8OHdG as a marker for Huntington disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

8OHdG is not a biomarker for Huntington disease state or progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.24

The measurement of abnormal movement: methods developed for Huntington's disease

31 March 2020

1 reference

12 December 2020

Corpus callosal atrophy in premanifest and early Huntington's disease

1 reference

12 December 2020

Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy

1 reference

12 December 2020

Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease.

1 reference

12 December 2020

Natural History of Huntington Disease

1 reference

12 December 2020

Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.

1 reference

12 December 2020

fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2014.24

1 reference

Dimensions Publication ID

26 June 2017

1049649920

0 references

1 reference